SCHEMBL3084039

SCHEMBL3084039

CC1CNC(=O)c2cc3ccc(C(=O)Nc4cnc5ccccc5c4)cc3n21

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 4/20 0.72
RPS6KA2 Q15349 17/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13143347 0.86 RPS6KA2 (0.80) RPS6KA3RPS6KA2
SCHEMBL14973148 0.84 RPS6KA3 (1.00) RPS6KA3RPS6KA2
SCHEMBL1991945 0.84 RPS6KA3 (1.00) RPS6KA3RPS6KA2
SCHEMBL3088023 0.83 RPS6KA3 (1.00) RPS6KA3RPS6KA2
SCHEMBL14892002 0.83 RPS6KA3 (1.00) RPS6KA3RPS6KA2
SCHEMBL13143301 0.83 RPS6KA2 (0.73) RPS6KA3RPS6KA2
SCHEMBL1978470 0.83 RPS6KA2 (1.00) RPS6KA3RPS6KA2
SCHEMBL13143374 0.82 RPS6KA2 (0.71) RPS6KA3RPS6KA2
SCHEMBL13143335 0.82 RPS6KA2 (0.71) RPS6KA3RPS6KA2
SCHEMBL13143316 0.82 RPS6KA2 (0.71) RPS6KA3RPS6KA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790712-B2 Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) 2010-09-07 US disclosed
US-7790712-B2 Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) 2010-09-07 US disclosed
US-7790712-B2 Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) 2010-09-07 US disclosed
US-20060276453-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276453-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 RPS6KA3 302/4885RPS6KA2 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.